Editor's note

This ExpertREACT article was originally published on 10 August 2009. Pipeline data and company positions described reflect the state of knowledge at that date.

121 projects: pipeline expansion continues

VacZine Analytics conducted full vaccine pipeline reviews in April 2008, October 2008 and August 2009, recording 97, 115 and 121 projects in clinical development respectively across Western commercial companies. This consistent upward trend - a 15-20% increase per period - demonstrated that despite the absence of major new product launches, the industry continued investing in new vaccine development. Excluding programmes related to secondary market launches, line extensions, biodefence and pandemic influenza, the pipeline's core growth was driven primarily by Phase I new entrants in influenza and global initiative categories (HIV, malaria, TB). The top six vaccine companies (including AstraZeneca/Medimmune) accounted for approximately 40-45% of all recorded programmes.

The H1N1 "swine flu" outbreak in April 2009 made pandemic influenza R&D more relevant than ever to pipeline metrics. Prior to the H1N1 outbreak there were approximately 21 pandemic influenza clinical trials recorded in October 2008. By August 2009 this figure had risen to 37 - with 25 new entries of which H1N1 accounted for around 20-30% of pandemic activity and approximately 5% of the total pipeline. H1N1 had also stimulated further activity in H5N1 and other viruses with pandemic potential, as well as a wave of new seasonal influenza programmes. Smaller technology-focused companies such as Protein Sciences and Novavax - previously held back by limited funding - were now making headway as authorities recognised the value of platform diversity.

Vaccine pipeline growth (2008-2009)
97 → 121
Vaccine projects in clinical development across three pipeline reviews (April 2008, Oct 2008, Aug 2009); pandemic influenza driving much of the new activity

Novel technologies and universal influenza ambitions

Analysis showed that a large proportion of current pipeline activity used novel or proprietary technologies including new adjuvants, VLP approaches and cell-culture derived vaccines. The proportion of programmes using novel adjuvant systems was growing, particularly within the influenza segment where both antigen-sparing and broader cross-protection ambitions were driving investment. Universal influenza vaccine concepts - targeting conserved influenza A proteins to provide cross-protection across multiple strains - were gaining traction in early-stage academic and company programmes, though commercial candidates remained at Phase I stages.